ArticleCell biochemistry and biophysics2026
Umbilical Cord Mesenchymal Stem Cells Improve PINK1/PARKIN-Mediated Mitophagy Inhibition in Preeclampsia.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPreeclampsia (PE) is a progressive multisystem disorder that arises after 20 weeks of gestation and poses severe risks to both maternal and fetal health. Umbilical cord mesenchymal stem cells (UC-MSCs) exhibit antioxidant and pro-angiogenic properties, which have been shown to be effective in treating various diseases.
methodsHTR8/SVneo cells were induced by lipopolysaccharide (LPS) to establish a PE cell model. Western blot (WB) and real-time quantitative PCR (RT-qPCR) were conducted to detect the expression of genes related to mitophagy. Meanwhile, ATP level was detected using an ATP content assay kit and mitochondrial membrane potential (MMP) level was detected under a fluorescence microscope using an MMP detection kit. Next, a PE rat model was induced using N(ω)-nitro-l-arginine methyl ester (L-NAME), followed by UC-MSCs transplantation. Enzyme-linked immunosorbent assay (ELISA) was used to measure serum levels of PE biomarkers, and the expression of mitophagy related genes was assessed via RT-qPCR, WB, and immunohistochemistry.
resultsUC-MSCs modulated the levels of Phosphatase and Tensin Homolog-induced Kinase 1 (PINK1), Parkin RBR E3 ubiquitin protein ligase (PARKIN), reversed the inhibition of mitophagy in the PE model and increased both ATP content and MMP. Importantly, UC-MSCs alleviated hypertension and proteinuria in PE rats, improved pregnancy outcomes, and mitigated the imbalance in angiogenesis.
conclusionThis study demonstrates that UC-MSCs improve PE trophoblast injury and vascularization imbalance through regulating mitochondrial autophagy. Our results indicate that UC-MSCs may hold significant potential for treating PE.Clinical trial number Not applicable.
Indexed as
Identifiers
42789013What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.